When building your watch list, focus on stocks with an 80 or higher RS Rating. Kymera Therapeutics now meets that criteria, with a jump from 80 to 85 Monday.
This proprietary rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks matches up against that of all other stocks.
Over 100 years of market history reveals that the top-performing stocks typically have an RS Rating north of 80 as they launch their biggest runs.
Hone Your Stock-Picking Skills By Focusing On These Factors
Kymera Therapeutics is building a consolidation with a 53.27 buy point. See if the stock can break out in heavy volume.
The company posted 0% earnings growth in the latest quarterly report. Sales increased -21%.
Kymera Therapeutics earns the No. 117 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Corcept Therapeutics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
